Australian Competition and Consumer Commission v Emerald Ocean Distributors Pty Ltd
[2001] FCA 982
At a glance
Source factsCourt
Federal Court of Australia
Decision date
2001-07-25
Before
Nicholson J, French J
Source
Original judgment source is linked above.
Judgment (9 paragraphs)
REASONS FOR JUDGMENT ON MOTION FOR LEAVE TO APPEAL 1 By proceedings instituted on 19 July 2000, the Australian Competition and Consumer Commission ("ACCC") sues Emerald Ocean Distributors Pty Ltd ("Emerald") and Slendertone Health and Beauty Pty Ltd ("Slendertone) and their common director and secretary, Sean O'Donoghue. The actual action arises out of the supply and promotion by Emerald and Slendertone of certain products described as "Slendertone Products". The products involve electronic muscle stimulation to tone and firm the body and abdominal muscles, reduce body measurements, remove cellulite and the like. They are marketed under the names: "Sequence 16" "Supreme" "Top Tone 12" "Gymbody 8" "Celluforme" The ACCC alleges that advertising of various of these products in magazines called Women's Health and Ultrafit in December 1999 and in March 2000 respectively, in Slendertone pamphlets and on a Slendertone web site in June 2000, involved false statements about the products in contravention of various provisions of the Trade Practices Act 1974 (Cth) and of the Fair Trading Acts of the various States and Territories. Sean O'Donoghue is said to have been knowingly involved in the contraventions. Relief claimed under the further amended application includes various declarations, injunctive relief, orders for corrective advertising and for Mr O'Donoghue to attend a Trade Practices Compliance Program seminar. Orders for refunds of moneys paid by members of the public who believe that they may have been misled or deceived by the respondents are also sought. 2 Emerald denies that it did any of the things alleged against it. Slendertone admits that it did various of the acts alleged but denies the implications of certain statements. And so far as it is said that statements made were in contravention of the Trade Practices Act or the Fair Trading Act it is pleaded that the statements were ones which the respondents had reasonable grounds for making. Their case is, in substance, that all of the statements in question were based upon information and literature provided to them by or on behalf of a company called Bio-Medical Research Ltd. 3 The proceedings have been in the docket of RD Nicholson J and subject to management by his Honour. By a motion filed on 14 February 2001, the respondents sought leave to file a cross-claim against two companies, BMR Ltd and Bio-Medical Research Ltd, both registered in the Republic of Ireland. They sought leave to serve it or, alternatively, notice of it on each of those companies out of the Commonwealth of Australia and in the Republic of Ireland. By the time the motion came on for hearing, a minute of proposed amended cross-claim had been filed. That sought relief only against Bio-Medical Research Ltd and not against BMR Ltd. 4 The proposed cross-claim refers to statements made by Slendertone in advertisements and on a web site and in its pamphlet, as particularised in the further amended statement of claim. In par 9 it is said that Slendertone and O'Donoghue made the statements referred to in the statement of claim for the sole reason that they were made to Slendertone by Bio-Medical Research Ltd and that O'Donoghue was advised by that company to repeat the statements to members of the public of Australia in the course of carrying on the business of selling the Slendertone products. The advice, it is said, was received at all times when O'Donoghue was in Australia. Slendertone and O'Donoghue say, in the cross-claim, that they admit having made the statements referred to in the statement of claim and admit having made some but not all of the implied statements referred to. They deny that all or any of the statements constitute misleading or deceptive conduct in trade or commerce as alleged by the ACCC or at all. 5 Paragraph 13 of the proposed amended cross-claim reads: "13. If, despite the matters pleaded in paragraphs 11 and 12, this Honourable Court finds: